Temitope Folaranmi - Concepedia

Author

Temitope Folaranmi

National Center for Immunization and Respiratory Diseases

Also Known As

Temitope A Folaranmi, Temitope A. Folaranmi, Temitope Folaranmi

Publications

947

Citations

H-Index

Concepts

All Affiliations

National Center for Immunization and Respiratory Diseases Merck & Co., Inc., Rahway, NJ, USA (United States)Epidemic Intelligence Service

About

Temitope Folaranmi is an author at National Center for Immunization and Respiratory Diseases specializing in public health, medicine, and vaccine surveillance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	512
2	Public Health	5	5	512
3	Epidemiology	4	4	458
4	Global Health	1	1	54
5	Health Informatics	1	1	54

Temitope Folaranmi

Publications

641

Citations

H-Index

Page 1

	Year	Citations
Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015 Jessica R. MacNeil, Lorry G. Rubin, Temitope Folaranmi, MMWR Morbidity and Mortality Weekly Report Young AdultsAdvisory CommitteeVaccine HesitancyPreventive MedicineVaccine Surveillance	2015	222
Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. Temitope Folaranmi, Lorry G. Rubin, Stacey W. Martin, PubMed Advisory CommitteeSecond Menb VaccineVaccine HesitancyPreventive MedicineVaccine Surveillance	2015	204
Increased Risk for Meningococcal Disease Among Men Who Have Sex With Men in the United States, 2012–2015 Temitope Folaranmi, Cécilia B. Kretz, Hajime Kamiya, Clinical Infectious Diseases	2017	72
mHealth in Africa: challenges and opportunities Temitope Folaranmi Perspectives in Public Health Incredible BoomHealthcare DeliveryE-healthGlobal Health ProgramConnected Health	2014	54
Nigeria's new government and public financing for universal health coverage Abiodun Awosusi, Temitope Folaranmi, Robert Yates The Lancet Global Health	2015	43
A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older Kenji Kawakami, Atsushi Nakamura, Akira Wakana, Human Vaccines & Immunotherapeutics ImmunodeficienciesPpsv23 ImmunizationPopulation Health SciencesChronic Medical ConditionPpsv23 Vaccination Rates	2019	17
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older Ulrike K. Buchwald, Charles P. Andrews, John Ervin, Human Vaccines & Immunotherapeutics ImmunodeficienciesImmunologyImmunodominanceHealthy Participants 50Vaccine Surveillance	2021	15
Systematic review and meta-analysis of pertussis epidemiology in Latin America and the Caribbean: 1980-2015. Temitope Folaranmi, Veronica Pinell-McNamara, Matthew Griffith, PubMed	2017	14

Page 1